Latest

Eli Lilly’s blockbuster oral weight-loss drug trial achieves new progress: After switching from injection to oral form, effective weight loss is maintained, and a marketing application has been submitted to the FDA.

Eli Lilly’s blockbuster oral weight-loss drug trial achieves new progress: After switching from injection to oral form, effective weight loss is maintained, and a marketing application has been submitted to the FDA.

Eli Lilly’s investigational oral weight-loss drug orforglipron has achieved a key milestone in its latest late-stage clinical trial, demonstrating that it can effectively help patients switching from injectables to maintain their weight-loss results. Given the drug’s clinical potential, Lilly announced Thursday that it has submitted a New Drug
Admin